Comparative Bioavailability of a Novel Fixed-dose Combination Etoricoxib and Tramadol

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Development

Background:

• Multimodal analgesia involves using multiple drugs or techniques to target diverse pain pathways, enhancing pain management.
• Etoricoxib and tramadol are commonly used analgesics, but their fixed-dose combination requires pharmacokinetic evaluation.

Purpose of the Study:

• To assess the pharmacokinetic profile and comparative bioavailability of a novel fixed-dose combination of etoricoxib 90 mg and tramadol 50 mg.
• To compare the novel combination against etoricoxib 90 mg and tramadol 50 mg administered as reference drugs in healthy Mexican volunteers.

Main Methods:

• A randomized, open-label, 3-way crossover study was conducted in 42 healthy Mexican adult volunteers.
• Subjects received single oral doses of etoricoxib 90 mg, tramadol 50 mg, or the fixed-dose combination after a 10-hour fast.
• Blood samples were analyzed using high-performance liquid chromatography coupled with tandem mass spectrometry to determine drug concentrations.

Main Results:

• The pharmacokinetic parameters (Cmax, AUC0-t, AUC0-∞) of the etoricoxib/tramadol fixed-dose combination were comparable to the reference products.
• Comparative bioavailability was established as confidence intervals for key pharmacokinetic metrics fell within the 80%-125% range.
• Non-serious adverse events were reported, with no significant safety concerns identified.

Conclusions:

• The etoricoxib/tramadol fixed-dose combination demonstrates comparable pharmacokinetic profiles and bioavailability to individual etoricoxib and tramadol.
• This novel combination represents a viable option for multimodal analgesia, potentially simplifying pain management regimens.
• Further clinical studies may explore its efficacy and safety in diverse patient populations experiencing various pain types.